In May 2023, NeuroSense Therapeutics Ltd. entered into a strategic business and scientific collaboration with a leading global biotechnology company that pioneers science and drives. | May 25, 2023
Sales Agreement On April 14, 2023, NeuroSense Therapeutics Ltd. entered into a Sales Agreement with A.G.P./Alliance Global Partners , pursuant to which the Company may offer. | April 14, 2023
NeuroSense Therapeutics Receives $4 Million Through Warrant Exercises - Warrants exercised at $6 per share - Extends cash runway through Q3 2023 . | March 25, 2022
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS - PrimeC, a novel combination therapy, demonstrated efficacy and safety in Phase IIa. | March 21, 2022